Velaglucerase Alfa
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Velaglucerase Alfa |
| DrugBank ID | DB06720 |
| Brand Names (EU) | Vpriv |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 96.99% |
Approved Indication (EMA)
Vpriv is indicated for long-term enzyme-replacement therapy (ERT) in patients with type-1 Gaucher disease.
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | Steel syndrome | 96.99% | DL |
| 2 | esophageal varices with bleeding | 96.20% | DL |
| 3 | esophageal varices without bleeding | 96.20% | DL |
| 4 | hypophosphatasia | 95.04% | DL |
| 5 | Gaucher disease | 94.16% | DL |
| 6 | Wolman disease with hypolipoproteinemia and acanthocytosis | 93.99% | DL |
| 7 | autosomal ichthyosis syndrome with fatal disease course | 93.74% | DL |
| 8 | cholesteryl ester storage disease | 92.90% | DL |
| 9 | varicose disease | 92.70% | DL |
| 10 | growth hormone insensitivity syndrome with immune dysregulation 2, autosomal dominant | 92.08% | DL |
| 11 | proximal myopathy with extrapyramidal signs | 92.06% | DL |
| 12 | reticular dysgenesis | 91.64% | DL |
| 13 | familial apolipoprotein C-II deficiency | 91.05% | DL |
| 14 | Charcot-Marie-Tooth disease | 90.61% | DL |
| 15 | skeletal muscle disease | 90.29% | DL |
| 16 | Wolman disease | 89.83% | DL |
| 17 | congenital Horner syndrome (disease) | 89.63% | DL |
| 18 | ptosis-vocal cord paralysis syndrome | 89.34% | DL |
| 19 | ptosis-strabismus-ectopic pupils syndrome | 89.07% | DL |
| 20 | congenital entropion | 88.71% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.